What does it take to ask one question — *how do you free software from hardware?* — and end up reshaping the entire computing industry? In this episode of Decoded, Dr. Jurgi Camblong speaks with Edouard Bugnion, co-founder of VMware and Vice President for Innovation and Impact at EPFL, the Swiss Federal Institute of Technology in Lausanne. VMware didn't just build a product. It built the foundation on which the modern cloud was built — and was acquired by Broadcom in 2023 for $69 billion. From a childhood in Neuchâtel to a PhD at Stanford, from research lab to billion-dollar company, and back to Switzerland as a professor and public advisor, Edouard has spent his career at the precise intersection of deep science and real-world impact. You'll hear how a single idea about separating software from hardware gave birth to an industry, what the dot-com crash taught him about building through uncertainty, the three factors he believes determine whether a company succeeds or fails, why the energy cost of AI is a problem that can't be wished away, and what it actually means to be responsible when innovation moves faster than society can keep up. This episode is about what happens when a scientist becomes a builder, and why the most important question in technology right now may not be *what can AI do* — but *what should it do.*

What does it take to turn a two-person startup in Paris into a $6.8 billion exit, and then do it all over again for 200 other founders?

In this episode of Decoded, Dr. Jurgi Camblong speaks with Bernard Liautaud, co-founder of BusinessObjects and Managing Partner at Balderton Capital, one of Europe's leading venture capital firms backing category-defining companies like Revolut, Wayve, and Quantum Systems.

Bernard didn't just build a company. He built a category. Starting with two people in Paris in 1990, he helped define what business intelligence could be, took the company to NASDAQ, and sold it to SAP for $6.8 billion. Then he turned that experience into fuel for the next generation of European founders.

You'll hear why Europe's VC returns have quietly outperformed the US, how Balderton evaluates founders and the one trait they call "insurgency," what the story of Revolut reveals about the power of execution, why Bernard believes Europe has not just the talent but the values to build AI responsibly, and the philosophy behind his most personal insight: as a VC, you have many shots. As a founder, you have one.

This episode is about what happens when ambition meets experience, and why Europe's most exciting chapter may still be ahead of us.

What happens when a world-class biologist decides that academic research isn't moving fast enough for patients? 

Dr. Keith Flaherty is a physician, scientist, and founder who obsesses over the "wiring of cells". As the Director of Clinical Research at the Mass General Hospital Cancer Center and a Professor of Medicine at Harvard Medical School, he has authored over 300 peer-reviewed research publications. But he didn't stop at academia. He went on to co-found Loxo Oncology and Scorpion Therapeutics, driving billions in acquisitions and fundamentally changing precision cancer care. 

In this episode, Keith joins Dr. Jurgi Camblong to discuss his journey from early cell biology to becoming president of the AACR. They explore the evolution of melanoma treatments, the mechanics of targeted inhibitors, and the friction in the system that prevents us from learning from every patient. 

Because better outcomes don’t come from better science alone. They come from making the whole system work. 

#Oncology #PrecisionMedicine #AACR #DrugDevelopment #DecodedPodcast

What happens when the mind behind the Mars Rovers turns its attention to fighting cancer and developing next-generation medicines?
Today, Thomas Fuchs is the Chief AI Officer at Eli Lilly & Company, but he started his career at NASA, building the AI that helped rovers navigate the surface of Mars. He soon realized that the same math used to distinguish sand from rocks could be used to identify cancer cells on a pathology slide. He transitioned to healthcare, coined the term "computational pathology", and secured the first-ever FDA approval for an AI solution in cancer pathology after founding Paige.ai.
In this episode, Thomas joins Dr. Jurgi Camblong to discuss his journey, including how to build trust around AI, the massive potential of the technology for medicine discovery, and what the future holds for medicine.

Because better outcomes don’t come from better algorithms alone—they come from pioneers brave enough to trust them.

For more information on this episode follow the link below:
https://www.linkedin.com/in/jurgicamblong/
https://www.sophiagenetics.com/podcasts/

#AIinHealthcare #DrugDiscovery #GenerativeAI #EliLilly #DecodedPodcast

Most doctors look at a tumor and see a disease. Professor Olivier Michielin sees a code waiting to be cracked. 

Starting his career in physics and training under Nobel Prize winner Martin Karplus, Olivier realized early on that he "would not be happy just talking to electrons". He pivoted to medicine to bring a data-driven, engineering mindset to oncology. Today, he is rewriting the rules of how we treat melanoma and other complex cancers by combining immunotherapy with advanced algorithms. 

In this episode, the "Tumor Hacker" joins Dr. Jurgi Camblong to discuss how he is using physics, AI, and immunotherapy to rewrite the future of oncology. From training with Nobel laureates to leading oncology at HUG, Olivier explains why the future of medicine isn’t about discovering cures by accident - it’s about engineering them by design. 

A conversation about the convergence of data, biology, and the human immune system. 

For more information on this episode follow the link below:

https://www.linkedin.com/in/jurgicamblong/
https://www.sophiagenetics.com/podcasts/

#Oncology #Immunotherapy #AIinHealthcare #PrecisionMedicine #DecodedPodcast

Are we practicing healthcare, or just "sick care"?

In this episode of Decoded, Jurgi Camblong sits down with Dr. Michael Snyder, Chair of Genetics at Stanford Medicine and one of the most cited scientists in the world, to challenge the status quo of modern medicine.

We monitor our cars with dashboards to prevent breakdowns, yet we wait until our bodies fail before seeking help. Dr. Snyder explains why the future of medicine isn't about treating illness—it's about predicting it.

In this episode, we cover:

The "Sick Care" Crisis: Why our current system is designed to fail and how to fix it.

The Body Dashboard: Using big data, AI, and wearables to monitor health in real-time.

Redefining Aging: How deep metabolic profiling can help us live longer, healthier lives.

The Future of Diagnostics: Moving from reactive treatments to proactive precision care.

Tune in to hear how data is rewriting the rules of human longevity.

Longevity is not luck. It is biology, variation, and human resilience expressed across generations - and we are only beginning to understand it. And few people have studied longevity more deeply than Professor Mayana Zatz, whose work with centenarians and supercentenarians is reshaping what we know about aging.

In this episode of Decoded, Dr. Jurgi Camblong speaks with one of the world’s leading geneticists and a pioneer in rare diseases, aging, and human longevity.

Based at the University of São Paulo, Mayana has followed more than 100,000 families to understand why some people develop severe genetic conditions while others remain healthy into their 90s, 100s, and beyond.

Together, they explore:

• What centenarians and supercentenarians reveal about healthy aging 
• Why some individuals stay healthy despite carrying high-risk mutations
• How genetic resilience may inspire future gene therapies
• What large family cohorts teach us about rare diseases and long-term health
• The role of prevention in the next era of medicine
• Why affordability must be part of the future of genetic treatments

A conversation that brings together genetics, aging research, and the real human stories behind long life. A deeper look at what it means to live longer, and live well.

#Longevity #Genetics #Aging #Centenarians #Supercentenarians #RareDisease #HumanResilience #GeneTherapy #HealthyAging #GenomicResearch #DecodedPodcast

In this episode, Dr. Jurgi Camblong travels to the University of Oxford to meet Professor Nicholas Proudfoot, one of the true pioneers of molecular biology. 

For more than five decades, Nick has helped decode life itself, revealing how genes are turned on and off, how RNA carries meaning beyond proteins, and how curiosity can drive discoveries that last a lifetime. 

Together, they revisit the early days of modern biology - a time before PCR or cloning - and trace how one generation of scientists transformed trial and error into the precision science we know today. 

From the discovery of the AAUAAA “full stop” that signals where genes end, to showing how DNA loops connect beginnings and endings, this is the story of how the foundations of modern genetics were built, one question at a time. 

You’ll hear about: 
 
• The birth of molecular biology, from improvisation to innovation. 
• The hidden power of noncoding RNAs and gene regulation. 
• The beauty and necessity of curiosity-driven research. 
• Why protecting fundamental science matters more than ever. 

Recorded in Oxford, this episode is a love letter to discovery - and to the mentors who remind us that innovation starts with a simple question: why? 

“All great discoveries begin with curiosity. 
If we stop funding curiosity-driven science, 
we stop funding the foundation of tomorrow’s medicine.” 
— Professor Nicholas Proudfoot, University of Oxford

A Conversation with Parminder Bhatia, Chief AI Officer, GE HealthCare

After three episodes with leaders in oncology and medicine - Prof. Malapelle (International Society of Liquid Biopsy), Dr. David Rhew (Microsoft), and Dr. Pedram Razavi (MSK), Jurgi turns to the question everyone’s asking:

How do we move from impressive demos to real impact at the bedside—at scale?

In this episode, Dr. Jurgi Camblong, Founder SOPHiA GENETICS, speaks with Parminder “Parry” Bhatia, Chief AI Officer at GE HealthCare, to unpack the hard parts of AI in medicine: earning clinical trust, fitting into workflows, proving value, and scaling safely across complex systems.

You’ll hear about:

• Adoption as the KPI
• The validation moat - building clinical-grade trust, calibration, and governance.
• Foundation models in imaging
• Real impact of AI in healthcare
• What’s next - agentic AI for tumor-board style decision support, and training clinicians to treat AI like a co-pilot they can question.

If you’re investing in, building, or deploying clinical AI, this is the playbook teams will be sharing. Listen on Spotify or Apple Podcasts.

Cancer has been described for a long time, yet only now are we beginning to truly decode it.

In this episode of Decoded, Dr. Jurgi Camblong, Founder of SOPHiA GENETICS, speaks with Dr. Pedram Razavi, Director of Liquid Biopsy and Cancer Genomics at Memorial Sloan Kettering Cancer Center. 

From the first historical mentions of tumors to today’s breakthroughs in precision oncology, Dr. Razavi shares how genomics, liquid biopsy, and AI are reshaping the way we detect, treat, and even think about cancer. Along the way, Dr. Razavi shares personal stories - the human moments that drive discovery.

In this exciting episode of Decoded, you'll hear:

• The evolving definition of cancer - what makes cancer “selfish,” and why some tumors adapt
• How breast oncology helped pioneer precision medicine
• Why liquid biopsy may let us anticipate resistance before it appears
• The art of oncology: data, science, and the patient in front of you

This conversation bridges history, science, and the future - for clinicians and researchers, patients and families, and anyone who wants to understand how cancer care is changing.